JAMA Author Interviews: Covering research in medicine, science, & clinical practice. For physicians, researchers, & clinicians.

Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD

August 16, 20163 min

Chat About Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD

For You